GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), ), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the appointment of Mario Saltarelli, M.D., Ph.D., as non-executive director of the Bioasis board of directors. Dr. Saltarelli served on Bioasis’ scientific advisory board (SAB) since June 2018.
“I am delighted to welcome Mario as the non-executive director of the Bioasis board. With a proven track record of building successful pipelines and programs, he brings to our board his broad leadership experience across multiple aspects of drug discovery and clinical development, with a focus in diseases of the central nervous system,” said Deborah Rathjen, Ph.D., Executive Chair and President & Chief Executive Officer of Bioasis. “We look forward to continuing to benefit from Mario’s expertise as we advance our xB3 programs toward the clinic.”
Dr. Saltarelli has over 20 years of leadership experience in the biopharmaceutical industry. Currently, he is Chief Medical Officer (CMO) at Entrada Therapeutics, and held CMO positions at Syntimmune and Annexon Biosciences. He previously held executive leadership positions at Vertex, Mallinckrodt, Shire, AbbVie, and Pfizer. Prior to entering the pharmaceutical industry, Dr. Saltarelli was an Assistant Professor of Neurology at Emory University School of Medicine in Atlanta. Dr. Saltarelli holds an M.D. and a Ph.D. in neuroscience from Johns Hopkins University School of Medicine in Baltimore and also completed his neurology residency training at Johns Hopkins Hospital. Dr. Saltarelli earned his B.S. in psychology from the University of Illinois at Urbana-Champaign.
“After having had the opportunity to contribute to Bioasis this past year as a member of the Scientific Advisory Board, I am thrilled to continue to advance my role within a company that I believe has strong potential to deliver therapeutics across the blood-brain barrier for the treatment of disorders with serious unmet medical needs,” said Dr. Saltarelli. “I look forward to continuing to work with the Company’s management to help develop these novel therapeutics.”
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3 TM platform, a proprietary technology for the delivery of therapeutics across the BBB and the treatment of CNS disorders in areas of high unmet medical need. The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. Bioasis’ internal pipeline programs are focused on treatments for orphan indications, including certain brain cancers, and rare diseases, including Gaucher’s Disease Type II. The Company maintains headquarters in Guilford, Connecticut. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more information about the Company, please visit www.bioasis.us.
+1 203 533 7082
Stern Investor Relations
+1 212 362 1200